Cardiff Oncology Newsroom

Cardiff Oncology Is Maintained at Overweight by Piper Sandler

Dow JonesDec 13 21:24 · Ratings

Cardiff Oncology Analyst Ratings

BenzingaDec 13 21:13 · Ratings

Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10

Futu NewsDec 13 20:31 · Ratings

TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating

Futu NewsDec 13 20:31 · Ratings

Cardiff Oncology Director Gary Pace Buys $940,199 in Stock

InvestingDec 13 05:10

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Zacks Dec 11 22:30

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BenzingaDec 11 05:05

US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift'

BenzingaDec 10 23:34

What's Going On With Cardiff Oncology Stock On Tuesday?

BenzingaDec 10 23:16

Cardiff Oncology Shares Rise 45% On Initial Positive Results in Colon Cancer Trial

WSJDec 10 23:02

Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating

Futu NewsDec 10 22:31 · Ratings

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday

MT NewswiresDec 10 22:07

Cardiff Oncology (CRDF) Gets a Buy From Craig-Hallum

TipRanksDec 10 21:55 · Ratings

Sector Update: Health Care

MT NewswiresDec 10 21:39

Top Premarket Gainers

MT NewswiresDec 10 21:13

Express News | Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

BreakingsDec 10 20:20

Cardiff Oncology Reports High Tumor Response in Mid-Stage Onvansertib Trial; Shares Rise Pre-Bell

MT NewswiresDec 10 19:52

Express News | Cardiff Oncology Inc - Additional Clinical Data From Crdf-004 Trial Expected in 1H 2025

BreakingsDec 10 19:00

Express News | Cardiff Oncology Inc - Onvansertib Well Tolerated at Both Doses

BreakingsDec 10 19:00

Express News | Cardiff Oncology Announces Positive Initial Data From First-Line Ras-Mutated Mcrc Clinical Trial

BreakingsDec 10 19:00